Moderna COVID-19 vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Moderna COVID-19 vaccine" in English language version.

refsWebsite

Global rank English rank

209web.archive.org

1^st place

43nih.gov

4^th place

26fda.gov

447^th place

338^th place

21doi.org

2^nd place

18cdc.gov

218^th place

212^th place

17tga.gov.au

3,984^th place

2,622^nd place

15europa.eu

68^th place

117^th place

14ghostarchive.org

32^nd place

21^st place

11modernatx.com

low place

9gov.uk

432^nd place

278^th place

9reuters.com

49^th place

47^th place

9canada.ca

1,712^th place

1,063^rd place

6swissmedic.ch

low place

6nytimes.com

7^th place

6semanticscholar.org

11^th place

8^th place

6who.int

195^th place

302^nd place

5handle.net

102^nd place

76^th place

5wsj.com

79^th place

65^th place

4statnews.com

8,771^st place

5,253^rd place

4cnbc.com

220^th place

155^th place

4cnn.com

28^th place

26^th place

3worldcat.org

5^th place

3usatoday.com

41^st place

34^th place

3clinicaltrials.gov

5,225^th place

4,062^nd place

2takeda.com

low place

2archive.today

14^th place

2aappublications.org

3,763^rd place

3,602^nd place

2france24.com

481^st place

508^th place

2acs.org

1,248^th place

1,104^th place

2nationalgeographic.com

344^th place

296^th place

2d18rn0p25nwr6d.cloudfront.net

5,980^th place

5,802^nd place

2forbes.com

54^th place

48^th place

2snopes.com

944^th place

678^th place

2yahoo.com

38^th place

40^th place

1nps.org.au

low place

1globo.com

62^nd place

304^th place

1gov.br

5,564^th place

8,920^th place

1hres.ca

low place

1hpfb-dgpsa.ca

low place

1bostonglobe.com

553^rd place

334^th place

1idsociety.org

low place

1cbc.ca

115^th place

82^nd place

1trackvaccines.org

low place

1contagionlive.com

low place

1cbsnews.com

108^th place

80^th place

1law.com

3,163^rd place

1,731^st place

1washingtonpost.com

34^th place

27^th place

1virological.org

low place

1grandforksherald.com

low place

8,013^th place

1masslive.com

2,719^th place

1,489^th place

1lonza.com

low place

1politico.eu

1,347^th place

909^th place

1thehill.com

476^th place

282^nd place

1cvdvaccine-us.com

low place

1fortune.com

433^rd place

284^th place

1jakartaglobe.id

low place

8,651^st place

1pfizer.com

low place

1bioworld.com

low place

1businessinsider.com

140^th place

115^th place

1bbc.com

20^th place

30^th place

1biospace.com

low place

7,595^th place

1fiercepharma.com

low place

8,921^st place

1swissinfo.ch

1,485^th place

1,650^th place

1npr.org

92^nd place

72^nd place

1biopharmadive.com

low place

1rapidmicrobiology.com

low place

1financialpost.com

3,491^st place

1,999^th place

1pharmatimes.com

low place

1marketwatch.com

1,303^rd place

808^th place

1inquirer.net

437^th place

260^th place

1gmanetwork.com

824^th place

488^th place

1europeanpharmaceuticalreview.com

low place

1hindustantimes.com

71^st place

52^nd place

1vnexpress.net

839^th place

2,307^th place

1galencentre.org

low place

1citynews1130.com

low place

1verifythis.com

low place

1globalnews.ca

985^th place

583^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1sps.nhs.uk

low place

1cdt.ch

low place

1gov.sg

low place

1straitstimes.com

543^rd place

346^th place

1theguardian.com

12^th place

11^th place

1pm.gc.ca

low place

7,458^th place

1apnews.com

129^th place

89^th place

1the-scientist.com

7,827^th place

5,905^th place

1latimes.com

22^nd place

19^th place

1nbcnews.com

137^th place

101^st place

1hhs.gov

5,973^rd place

3,693^rd place

1nature.com

234^th place

397^th place

1harvard.edu

18^th place

17^th place

1factcheck.org

7,075^th place

4,103^rd place

1lacounty.gov

8,130^th place

4,766^th place

aappublications.org

Jenco J (16 March 2021). "Moderna testing COVID-19 vaccine in children under 12". AAP News. Archived from the original on 3 November 2021. Retrieved 10 April 2021.
"Moderna testing COVID-19 vaccine in children under 12". American Academy of Pediatrics. 16 March 2021. Archived from the original on 3 November 2021. Retrieved 10 April 2021.

acs.org

cen.acs.org

Cross R (29 September 2020). "The tiny tweak behind COVID-19 vaccines". Chemical & Engineering News. 98 (38). Archived from the original on 16 February 2021. Retrieved 30 September 2020.
Mullin R (25 November 2020). "Pfizer, Moderna ready vaccine manufacturing networks". Chemical & Engineering News. American Chemical Society. Archived from the original on 11 December 2020. Retrieved 21 December 2020.

apnews.com

"No, Germany hasn't stopped using COVID-19 vaccines". AP News. 14 September 2022. Archived from the original on 3 October 2022. Retrieved 3 October 2022.

archive.today

"Moderna Spikevax COVID-19 vaccines". Health Canada. 12 September 2023. Archived from the original on 15 September 2023. Retrieved 15 September 2023.
Judd A (12 September 2023). "Get ready for significant COVID, flu fall vaccine campaign, B.C. government says". Global News. Archived from the original on 13 September 2023. Retrieved 15 September 2023.

bbc.com

"Dolly Parton 'honoured and proud' to help Covid-19 battle". BBC News. 18 November 2020. Archived from the original on 19 August 2021. Retrieved 14 August 2021.

biopharmadive.com

Pagliarulo N, ed. (17 September 2020). "Moderna, in bid for transparency, discloses detailed plan of coronavirus vaccine trial". BioPharma Dive. Archived from the original on 16 November 2020. Retrieved 18 September 2020.

biospace.com

Keown A (7 May 2020). "Moderna moves into Phase II testing of COVID-19 vaccine candidate". BioSpace. Archived from the original on 16 November 2020. Retrieved 9 May 2020.

bioworld.com

Carey K (26 February 2020). "Increasing number of biopharma drugs target COVID-19 as virus spreads". BioWorld. Archived from the original on 27 February 2020. Retrieved 1 March 2020.

bostonglobe.com

Mandavilli A (19 June 2022). "CDC recommends COVID-19 vaccines for children under 5". The New York Times. Archived from the original on 21 June 2022. Retrieved 21 June 2022.

businessinsider.com

markets.businessinsider.com

Everett G (27 February 2020). "These 5 drug developers have jumped this week on hopes they can provide a coronavirus treatment". Markets Insider. Archived from the original on 16 November 2020. Retrieved 1 March 2020.

canada.ca

covid-vaccine.canada.ca

"Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2)". Health Canada. 23 December 2020. Archived from the original on 23 December 2020. Retrieved 23 December 2020.
"Regulatory Decision Summary - COVID-19 Vaccine Moderna". Health Canada. 27 August 2021. Archived from the original on 27 August 2021. Retrieved 28 August 2021.
"Spikevax (elasomeran mRNA vaccine) Monograph" (PDF). Archived from the original (PDF) on 3 December 2021.
"Regulatory Decision Summary - Spikevax". Health Canada. 13 November 2020. Archived from the original on 17 September 2021. Retrieved 18 September 2021.
"Regulatory Decision Summary - Spikevax Bivalent". Health Canada. 1 September 2022. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
"Regulatory Decision Summary – Moderna COVID-19 Vaccine". Health Canada. 23 December 2020. Archived from the original on 15 January 2021. Retrieved 23 December 2020.
"Spikevax Bivalent". Health Canada. 1 September 2022. Archived from the original on 30 October 2022. Retrieved 30 October 2022.

canada.ca

"Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications". Health Canada. 17 September 2020. Archived from the original on 10 January 2022. Retrieved 17 September 2021.
"Moderna Spikevax COVID-19 vaccines". Health Canada. 12 September 2023. Archived from the original on 15 September 2023. Retrieved 15 September 2023.

cbc.ca

Boisvert N (1 September 2022). "Health Canada approves updated Moderna vaccine for Omicron variant". CBC News. Archived from the original on 1 September 2022. Retrieved 1 September 2022.

cbsnews.com

Smith K (24 April 2021). "New CDC guidance recommends pregnant people get the COVID-19 vaccine". CBS News. Archived from the original on 24 April 2021. Retrieved 24 April 2021.

cdc.gov

"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived from the original (PDF) on 14 August 2021. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years Through 17 Years of Age" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived (PDF) from the original on 16 July 2022. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 Years through 11 Years of Age" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived (PDF) from the original on 16 July 2022. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 Months Through 5 Years of Age" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived (PDF) from the original on 16 July 2022. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"COVID-19 Vaccines for Moderately to Severely Immunocompromised People". U.S. Centers for Disease Control and Prevention (CDC). 13 August 2021. Archived from the original on 10 December 2021. Retrieved 13 August 2021.
"CDC Recommends the First Updated COVID-19 Booster" (Press release). U.S. Centers for Disease Control and Prevention (CDC). 1 September 2022. Archived from the original on 2 September 2022. Retrieved 1 September 2022.
Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 29 March 2021. This article incorporates text from this source, which is in the public domain.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521. Archived (PDF) from the original on 5 February 2022. Retrieved 15 September 2021.
"Vaccination Considerations for People Pregnant or Breastfeeding". U.S. Centers for Disease Control and Prevention (CDC). 18 March 2021. Archived from the original on 5 January 2022. Retrieved 24 April 2021. This article incorporates text from this source, which is in the public domain.
Shimabukuro T (1 March 2021). "COVID-19 Vaccine Safety Update" (PDF). U.S. Centers for Disease Control and Prevention. Archived (PDF) from the original on 7 June 2021. Retrieved 30 March 2021.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (4): 125–129. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. Archived (PDF) from the original on 1 September 2021. Retrieved 25 April 2021.{{cite journal}}: CS1 maint: numeric names: authors list (link) This article incorporates text from this source, which is in the public domain.
"Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines". U.S. Centers for Disease Control and Prevention (CDC). 3 June 2022. Archived from the original on 27 June 2021. Retrieved 27 June 2021. This article incorporates text from this source, which is in the public domain.
National Center for Immunization and Respiratory Diseases (23 June 2021). "Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination". Centers for Disease Control and Prevention. Archived from the original on 3 July 2021. Retrieved 2 July 2021.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–6. doi:10.15585/mmwr.mm695152e1. ISSN 0149-2195. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 21 December 2020. This article incorporates text from this source, which is in the public domain.
"Coronavirus Disease 2019". Centers for Disease Control and Prevention (Press release). 10 January 2022. Archived from the original on 4 February 2022. Retrieved 4 February 2022.
"CDC Expands Eligibility for COVID-19 Booster Shots". U.S. Centers for Disease Control and Prevention (CDC). 21 October 2021. Archived from the original on 7 December 2021. Retrieved 22 October 2021. This article incorporates text from this source, which is in the public domain.
Priddy F (12 September 2023). "Safety and Immunogenicity of Moderna COVID-19 Vaccine (2023-2024 Formula) - Monovalent XBB.1.5 Variant Vaccine" (PDF). Centers for Disease Control and Prevention. Archived (PDF) from the original on 15 September 2023. Retrieved 15 September 2023.
"COVID-19 Vaccine Facts". Centers for Disease Control and Prevention. 18 August 2021. Archived from the original on 11 December 2021. Retrieved 27 August 2021.

cdt.ch

"Covid-19, Swissmedic autorizza il vaccino aggiornato di Moderna". Corriere del Ticino (in Italian). 10 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.

citynews1130.com

Casaletto L (16 September 2021). "Pfizer, Moderna vaccines granted full approval by Health Canada; get name change". CityNews. Archived from the original on 10 January 2022. Retrieved 17 September 2021.

clinicaltrials.gov

Clinical trial number NCT04405076 for "Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older" at ClinicalTrials.gov
Clinical trial number NCT04470427 for "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19" at ClinicalTrials.gov
"A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants". ClinicalTrials.gov. 15 June 2021. Archived from the original on 6 August 2021. Retrieved 5 August 2021.

cnbc.com

Lovelace Jr B, Higgins-Dunn N (16 November 2020). "Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar". CNBC. Archived from the original on 16 November 2020. Retrieved 17 November 2020.
Li Y (14 July 2020). "Dow futures jump more than 200 points after Moderna says its vaccine produces antibodies to coronavirus". CNBC. Archived from the original on 16 November 2020. Retrieved 15 July 2020.
Tirrell M (14 January 2021). "Moderna looks to test Covid-19 booster shots a year after initial vaccination". CNBC. Archived from the original on 10 January 2022. Retrieved 18 January 2021.
Taylor C (8 October 2021). "Nordic countries are restricting the use of Moderna's Covid vaccine. Here's why". CNBC. Archived from the original on 2 October 2022. Retrieved 2 October 2022.

cnn.com

Kuznia R, Polglase K, Mezzofiore G (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.
Mascarenhas L (1 October 2020). "Moderna chief says Covid-19 vaccine could be widely available by late March". CNN. Archived from the original on 16 November 2020. Retrieved 2 October 2020.
Cohen E (22 October 2020). "First large-scale US Covid-19 vaccine trial reaches target of 30,000 participants". CNN. Archived from the original on 16 November 2020. Retrieved 23 October 2020.
Cohen E (30 November 2020). "Moderna applies for FDA authorization for its Covid-19 vaccine". CNN. Archived from the original on 3 December 2020. Retrieved 4 December 2020.

contagionlive.com

Kunzmann K (31 December 2020). "Moderna Vaccine Shows Significant COVID-19 Prevention Efficacy in Phase 3 Data". Contagion Live. Archived from the original on 1 February 2022.

cvdvaccine-us.com

"Pfizer-BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling". Pfizer. Archived from the original on 1 February 2022. Retrieved 17 December 2020.

d18rn0p25nwr6d.cloudfront.net

"Annual Report for the fiscal year ended December 31, 2020; 10-K SEC filing" (PDF). Moderna Inc. 16 February 2021. Archived (PDF) from the original on 8 December 2021. Retrieved 3 May 2022.
"Annual Report for the fiscal year ended December 31, 2021; 10-K SEC filing" (PDF). Moderna Inc. 25 February 2022. Archived (PDF) from the original on 7 March 2022. Retrieved 3 May 2022.

doi.org

"Elasomeran for prevention of COVID-19". Australian Prescriber. 44 (5): 172. October 2021. doi:10.18773/austprescr.2021.048. PMC 8542485. PMID 34728884. Archived from the original on 14 May 2022. Retrieved 14 May 2022.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. (February 2021). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine". The New England Journal of Medicine. 384 (5): 403–416. doi:10.1056/NEJMoa2035389. PMC 7787219. PMID 33378609.
Mishra SK, Tripathi T (February 2021). "One year update on the COVID-19 pandemic: Where are we now?". Acta Tropica. 214: 105778. doi:10.1016/j.actatropica.2020.105778. PMC 7695590. PMID 33253656.
Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC (February 2021). "COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines". European Review for Medical and Pharmacological Sciences. 25 (3): 1663–1669. doi:10.26355/eurrev_202102_24877. PMID 33629336.
Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 29 March 2021. This article incorporates text from this source, which is in the public domain.
Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al. (June 2021). "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19". N Engl J Med. 384 (23): 2259–2261. doi:10.1056/NEJMc2103916. PMC 8524784. PMID 33822494.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R (September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521. Archived (PDF) from the original on 5 February 2022. Retrieved 15 September 2021.
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. (2 November 2021). "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar". Nature Medicine. 27 (12): 2136–2143. doi:10.1038/s41591-021-01583-4. hdl:10576/24856. ISSN 1546-170X. PMID 34728831. S2CID 241108406. Tables 3 and 5
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). "Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study". BMJ. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165. Tables 6 and 7
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. (June 2021). "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons". The New England Journal of Medicine. 384 (24): 2273–2282. doi:10.1056/NEJMoa2104983. PMC 8117969. PMID 33882218.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (4): 125–129. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. Archived (PDF) from the original on 1 September 2021. Retrieved 25 April 2021.{{cite journal}}: CS1 maint: numeric names: authors list (link) This article incorporates text from this source, which is in the public domain.
Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. (April 2021). "Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2". The New England Journal of Medicine. 384 (13): 1273–1277. doi:10.1056/NEJMc2102131. PMC 7944952. PMID 33657292.
Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. (January 2022). "Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021". JAMA. 327 (4): 331–340. doi:10.1001/jama.2021.24110. PMC 8790664. PMID 35076665.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (November 2020). "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report". The New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912.
Dolgin E (November 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology. doi:10.1038/d41587-020-00022-y. PMID 33239758. S2CID 227176634.
Mateus J, Dan JM, Zhang Z, Moderbacher CR, Lammers M, Goodwin B, et al. (2021). "Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells". Science. 374 (6566): eabj9853. doi:10.1126/science.abj9853. PMC 8542617. PMID 34519540.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–6. doi:10.15585/mmwr.mm695152e1. ISSN 0149-2195. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 21 December 2020. This article incorporates text from this source, which is in the public domain.
"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (Editorial). 596 (7872): 317. 17 August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262. Archived from the original on 21 October 2021. Retrieved 21 August 2021.
"Moderna loses key patent challenge". Nature Biotechnology. 38 (9): 1009. September 2020. doi:10.1038/s41587-020-0674-1. PMID 32887970. S2CID 221504018.

europa.eu

ema.europa.eu

"Spikevax (previously COVID-19 Vaccine Moderna) EPAR". European Medicines Agency (EMA). 4 January 2021. Archived from the original on 1 February 2022. Retrieved 31 January 2022.
"EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines". European Medicines Agency (Press release). 16 September 2022. Archived from the original on 16 September 2022. Retrieved 18 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.
"Comirnaty and Spikevax: EMA recommendations on extra doses boosters". European Medicines Agency (EMA) (Press release). 4 October 2021. Archived from the original on 11 December 2021. Retrieved 4 October 2021.
"COVID-19 vaccines safety update" (PDF). European Medicines Agency. 3 August 2022. Archived (PDF) from the original on 3 August 2022. Retrieved 3 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU" (Press release). European Medicines Agency (EMA). 6 January 2021. Archived from the original on 17 March 2021. Retrieved 6 January 2021.
"COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU". European Medicines Agency (EMA) (Press release). 23 July 2021. Archived from the original on 26 November 2021. Retrieved 10 November 2021.
"EMA evaluating data on booster dose of COVID-19 vaccine Spikevax". European Medicines Agency (EMA) (Press release). 27 September 2021. Archived from the original on 27 September 2021. Retrieved 27 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"ECDC and EMA highlight considerations for additional booster doses of COVID-19 vaccines". European Medicines Agency (EMA) (Press release). 2 September 2021. Archived from the original on 28 September 2021. Retrieved 27 September 2021.
"ETF recommends updating COVID-19 vaccines to target new JN.1 variant". European Medicines Agency (EMA). 30 April 2024. Retrieved 13 September 2024.
"Archived copy" (PDF). Archived (PDF) from the original on 13 September 2024. Retrieved 13 September 2024.{{cite web}}: CS1 maint: archived copy as title (link)

ec.europa.eu

"European Commission authorises second safe and effective vaccine against COVID-19". European Commission (Press release). 6 January 2021. Archived from the original on 20 January 2021. Retrieved 6 January 2021.
"COVID-19 Vaccine Moderna". Europa. 22 July 2022. Archived from the original on 10 January 2022.
"Spikevax Product information". Union Register of medicinal products. Archived from the original on 24 January 2021. Retrieved 3 March 2023.
"Coronavirus: Commission approves contract with Moderna to ensure access to a potential vaccine". European Commission. 25 November 2020. Archived from the original on 10 January 2022. Retrieved 4 December 2020.

europeanpharmaceuticalreview.com

Balfour H (2 November 2020). "Takeda to supply Japan with Moderna's COVID-19 vaccine". European Pharmaceutical Review. Archived from the original on 10 January 2022.

factcheck.org

Fichera A (14 May 2021). "Magnet Videos Refuel Bogus Claim of Vaccine Microchips". FactCheck.org. Annenberg Public Policy Center. Archived from the original on 17 May 2021. Retrieved 7 June 2021.

fda.gov

"FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA). 11 September 2023. Archived from the original on 11 September 2023. Retrieved 12 September 2023. This article incorporates text from this source, which is in the public domain.
"FDA Takes Key Action by Approving Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 31 January 2022. Archived from the original on 31 January 2022. Retrieved 31 January 2022. This article incorporates text from this source, which is in the public domain.
"Spikevax and Moderna COVID-19 Vaccine". U.S. Food and Drug Administration (FDA). 17 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age". U.S. Food and Drug Administration (FDA) (Press release). 17 June 2022. Archived from the original on 17 June 2022. Retrieved 17 June 2022.
"Fact Sheet for Healthcare Providers Administering Vaccine" (PDF). U.S. Food and Drug Administration (FDA). 31 January 2022. Archived from the original on 1 February 2022. Retrieved 13 August 2021.
"Moderna COVID-19 Vaccine Emergency Use Authorization" (PDF). U.S. Food and Drug Administration (FDA). 17 June 2022. Archived from the original on 14 August 2021. Retrieved 17 June 2022. This article incorporates text from this source, which is in the public domain.
"FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals". U.S. Food and Drug Administration (FDA) (Press release). 12 August 2021. Archived from the original on 7 December 2021. Retrieved 13 August 2021. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose" (Press release). U.S. Food and Drug Administration (FDA). 31 August 2022. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
"Moderna COVID-19 Vaccine". U.S. Food and Drug Administration (FDA). 7 July 2021. Archived from the original on 23 January 2021. Retrieved 5 August 2021.
"Vaccines and Related Biological Products Advisory Committee Meeting" (PDF). U.S. Food and Drug Administration (FDA). 17 December 2020. Archived from the original on 1 January 2022. Retrieved 23 December 2020.
"VRBPAC mRNA-1273 Sponsor Briefing Document" (PDF). Moderna. 17 December 2020. Archived from the original on 13 May 2021. Retrieved 1 January 2021.
"Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 25 February 2021. Archived from the original on 25 February 2021. Retrieved 25 February 2021. This article incorporates text from this source, which is in the public domain.
"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 18 December 2020. Archived from the original on 17 March 2021. Retrieved 18 December 2020. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccines". U.S. Food and Drug Administration. 20 April 2023. Archived from the original on 7 October 2022. Retrieved 23 April 2023.
"Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines". U.S. Food and Drug Administration (Press release). 18 April 2023. Archived from the original on 23 April 2023. Retrieved 23 April 2023.
"Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months". U.S. Food and Drug Administration (FDA) (Press release). 7 January 2022. Archived from the original on 4 February 2022. Retrieved 4 February 2022.
"FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines". U.S. Food and Drug Administration (FDA) (Press release). 21 October 2021. Archived from the original on 7 December 2021. Retrieved 22 October 2021. This article incorporates text from this source, which is in the public domain.
"FDA Expands Eligibility for COVID-19 Vaccine Boosters". U.S. Food and Drug Administration (FDA) (Press release). 19 November 2021. Archived from the original on 19 November 2021. Retrieved 19 November 2021. This article incorporates text from this source, which is in the public domain.
"FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months". U.S. Food and Drug Administration (FDA) (Press release). 7 January 2022. Archived from the original on 7 January 2022. Retrieved 7 January 2022. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups". U.S. Food and Drug Administration (Press release). 12 October 2022. Archived from the original on 13 October 2022. Retrieved 13 October 2022. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age". U.S. Food and Drug Administration (Press release). 8 December 2022. Retrieved 25 January 2023.
"Spikevax". U.S. Food and Drug Administration (FDA). 11 September 2023. Archived from the original on 11 September 2023. Retrieved 12 September 2023.
"Moderna COVID-19 Vaccine". U.S. Food and Drug Administration (FDA). 11 September 2023. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
"FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (Press release). 22 August 2024. Archived from the original on 13 September 2024. Retrieved 26 August 2024. This article incorporates text from this source, which is in the public domain.

precision.fda.gov

"UNII - TYF7YW7ENF". precisionFDA. Archived from the original on 13 September 2024. Retrieved 6 October 2023.
"UNII - 4F9QRS7ZV2". precisionFDA. Archived from the original on 13 September 2024. Retrieved 6 October 2023.

fiercepharma.com

Blankenship K (1 May 2020). "Moderna aims for a billion COVID-19 shots a year with Lonza manufacturing tie-up". Fierce Pharma. Archived from the original on 16 November 2020.

financialpost.com

Kuchler H (30 November 2020). "Canada could be among the first to clear Moderna's COVID-19 vaccine for use". The Financial Post. Archived from the original on 4 December 2020. Retrieved 4 December 2020.

forbes.com

Hart R (10 November 2021). "Germany, France Restrict Moderna's Covid Vaccine For Under-30s Over Rare Heart Risk—Despite Surging Cases". Forbes. Archived from the original on 2 October 2022. Retrieved 3 October 2022.
Vardi N (29 June 2020). "Moderna's Mysterious Coronavirus Vaccine Delivery System". Forbes. Archived from the original on 6 January 2021. Retrieved 1 December 2020.

fortune.com

McGregor G (5 December 2020). "How China's COVID-19 could fill the gaps left by Pfizer, Moderna, AstraZeneca". Fortune. Archived from the original on 12 December 2020. Retrieved 5 December 2020.

france24.com

"Moderna says Covid vaccine durable for at least six months". France 24. Agence France-Presse. 5 August 2021. Archived from the original on 11 August 2021. Retrieved 11 August 2021.
"France advises against Moderna for under-30s over rare heart risk". France 24. 9 November 2021. Retrieved 3 October 2022.

galencentre.org

codeblue.galencentre.org

"NPRA Approves Moderna Covid-19 Vaccine". CodeBlue. 5 August 2021. Archived from the original on 7 August 2021. Retrieved 8 August 2021.

ghostarchive.org

"Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications". Health Canada. 17 September 2020. Archived from the original on 10 January 2022. Retrieved 17 September 2021.
"COVID-19 Vaccine Moderna". Europa. 22 July 2022. Archived from the original on 10 January 2022.
"Storage & Handling". Moderna. 11 August 2021. Archived from the original on 10 January 2022. Retrieved 11 August 2021.
"Moderna Use Roche Antibody Test During Vaccine Trials". rapidmicrobiology.com. 10 December 2020. Archived from the original on 10 January 2022. Retrieved 13 December 2020.
Luthra S (23 November 2020). "Pregnant women haven't been included in promising COVID-19 vaccine trials". USA Today. Archived from the original on 10 January 2022.
Krubiner C, Faden RR, Karron RA (9 December 2020). "FDA: Leave the door open to Covid-19 vaccination for pregnant and lactating health workers". STAT. Archived from the original on 10 January 2022.
"Singapore becomes first in Asia to approve Moderna's COVID-19 vaccine". Reuters. 3 February 2021. Archived from the original on 10 January 2022. Retrieved 3 February 2021.
Balfour H (2 November 2020). "Takeda to supply Japan with Moderna's COVID-19 vaccine". European Pharmaceutical Review. Archived from the original on 10 January 2022.
Casaletto L (16 September 2021). "Pfizer, Moderna vaccines granted full approval by Health Canada; get name change". CityNews. Archived from the original on 10 January 2022. Retrieved 17 September 2021.
Tirrell M (14 January 2021). "Moderna looks to test Covid-19 booster shots a year after initial vaccination". CNBC. Archived from the original on 10 January 2022. Retrieved 18 January 2021.
Grady D, Mandavilli A, Thomas K (25 January 2021). "Is the Covid-19 Vaccine Effective Against New South African Variant?". The New York Times. Archived from the original on 10 January 2022. Retrieved 25 January 2021.
"Coronavirus: Commission approves contract with Moderna to ensure access to a potential vaccine". European Commission. 25 November 2020. Archived from the original on 10 January 2022. Retrieved 4 December 2020.
"New agreements to secure additional vaccine candidates for COVID-19". Prime Minister's Office, Government of Canada. 25 September 2020. Archived from the original on 10 January 2022. Retrieved 4 December 2020.
Evon D (2 November 2021). "'Luciferase' Is Not an Ingredient in COVID-19 Vaccines". Snopes.com. Archived from the original on 10 January 2022.

globalnews.ca

Judd A (12 September 2023). "Get ready for significant COVID, flu fall vaccine campaign, B.C. government says". Global News. Archived from the original on 13 September 2023. Retrieved 15 September 2023.

globo.com

oglobo.globo.com

Rosário M (26 June 2023). "Anvisa aprova vacina bivalente da Moderna para Covid-19". O Globo (in Brazilian Portuguese). Archived from the original on 22 May 2024. Retrieved 21 June 2024.

gmanetwork.com

Lopez V (5 May 2021). "Philippines grants EUA to Moderna's COVID-19 vaccine". GMA News Online. Archived from the original on 5 May 2021. Retrieved 5 May 2021.

gov.br

"Anvisa aprova registro da vacina Spikevax monovalente". Brazilian Health Regulatory Agency (in Brazilian Portuguese). 6 March 2024. Retrieved 21 June 2024.

gov.sg

"Securing Singapore's access to COVID-19 vaccines". www.gov.sg. Singapore Government. 14 December 2020. Archived from the original on 29 January 2021. Retrieved 1 February 2021.

gov.uk

"Summary of Product Characteristics for Spikevax". Medicines and Healthcare products Regulatory Agency (MHRA). 20 August 2021. Archived from the original on 18 February 2021. Retrieved 29 August 2021.
"Conditions of Authorisation for COVID-19 Vaccine Moderna". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Archived from the original on 18 February 2021. Retrieved 29 August 2021.
"Regulatory approval of Spikevax (formerly COVID-19 Vaccine Moderna)". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Archived from the original on 28 August 2021. Retrieved 29 August 2021.
"Summary of the Public Assessment Report for Spikevax". Medicines and Healthcare products Regulatory Agency (MHRA). 19 February 2021. Archived from the original on 22 April 2021. Retrieved 29 August 2021.
"First bivalent COVID-19 booster vaccine approved by UK medicines regulator" (Press release). Medicines and Healthcare products Regulatory Agency (MHRA). 15 August 2022. Archived from the original on 16 August 2022. Retrieved 16 August 2022.
"Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 15 August 2022. Archived from the original on 16 August 2022. Retrieved 16 August 2022.
"Regulatory approval of adapted Spikevax (formerly COVID-19 Vaccine Moderna) XBB.1.5 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 15 September 2023. Retrieved 7 October 2023.
"MHRA approves Moderna's adapted COVID-19 vaccine (Spikevax) that targets Omicron XBB.1.5". Medicines and Healthcare products Regulatory Agency (MHRA). 15 September 2023. Archived from the original on 21 September 2023. Retrieved 7 October 2023.
"MHRA approves Spikevax JN.1 COVID-19 vaccines for adults and children from infancy". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). Archived from the original on 3 September 2024. Retrieved 4 September 2024.

grandforksherald.com

Springer P (24 May 2021). "Fargo firm makes key ingredient for millions of COVID-19 vaccine doses". Grand Forks Herald. Archived from the original on 22 August 2021. Retrieved 25 May 2021.

handle.net

hdl.handle.net

Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 (Report). World Health Organization (WHO). February 2021. hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 2 May 2021.
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. (2 November 2021). "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar". Nature Medicine. 27 (12): 2136–2143. doi:10.1038/s41591-021-01583-4. hdl:10576/24856. ISSN 1546-170X. PMID 34728831. S2CID 241108406. Tables 3 and 5
World Health Organization (June 2021). "INN Proposed International Nonproprietary Names: List 125 COVID-19 (special edition)". WHO Drug Information. 35 (2): 578–9. hdl:10665/343367.
World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86". WHO Drug Information. 35 (3). hdl:10665/346562.
World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.

harvard.edu

ui.adsabs.harvard.edu

"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (Editorial). 596 (7872): 317. 17 August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262. Archived from the original on 21 October 2021. Retrieved 21 August 2021.

hhs.gov

"Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots" (Press release). United States Department of Health and Human Services. 18 August 2021. Archived from the original on 7 December 2021. Retrieved 21 August 2021.

hindustantimes.com

Kaul R (29 June 2021). "Moderna's Covid vaccine approved for use in India". Hindustan Times. Archived from the original on 20 October 2021. Retrieved 29 June 2021.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Summary Basis of Decision (SBD) for Spikevax XBB.1.5". Drug and Health Products Portal. 1 September 2012. Retrieved 11 December 2023.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Spikevax". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

idsociety.org

"Moderna COVID-19 Vaccine". Dosing & Administration. Infectious Diseases Society of America. 4 January 2021. Archived from the original on 20 December 2020. Retrieved 5 January 2021.

inquirer.net

newsinfo.inquirer.net

"WHO lists anti-COVID Moderna vaccine for emergency use". Philippine Daily Inquirer. Agence France-Presse. 1 May 2021. Archived from the original on 1 May 2021. Retrieved 1 May 2021.

jakartaglobe.id

"Pfizer's Vaccine Is Out of the Question as Indonesia Lacks Refrigerators: State Pharma Boss". Jakarta Globe. 22 November 2020. Archived from the original on 7 December 2020. Retrieved 5 December 2020.

lacounty.gov

publichealth.lacounty.gov

"COVID-19 Vaccine Myths and Facts" (PDF). Los Angeles County Department of Public Health. 15 December 2021. Archived (PDF) from the original on 25 August 2021. Retrieved 27 August 2021.

latimes.com

Hiltzik M (19 May 2020). "Column: Moderna's vaccine results boosted its share offering – and it's hardly a coincidence". The Los Angeles Times. Archived from the original on 16 November 2020. Retrieved 19 May 2020.

law.com

Auth DR, Powell MB (14 September 2020). "Patent Issues Highlight Risks of Moderna's COVID-19 Vaccine". New York Law Journal. Archived from the original on 15 October 2020. Retrieved 1 December 2020.

lonza.com

"Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands". www.lonza.com. 2 June 2021. Archived from the original on 25 December 2022. Retrieved 25 December 2022.

marketwatch.com

Lee J (16 December 2020). "Moderna nears its first-ever FDA authorization, for its COVID-19 vaccine". MarketWatch. Archived from the original on 16 April 2021. Retrieved 19 December 2020.

masslive.com

Cote J (4 May 2021). "Moderna to more than double size of Massachusetts facility, transform production and lab space to industrial tech center". MassLive. Archived from the original on 25 July 2021. Retrieved 28 May 2021.

medicines.org.uk

"Spikevax JN.1 0.1 mg/mL dispersion for injection". (emc). 3 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.

modernatx.com

investors.modernatx.com

"Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform". Moderna (Press release). 19 April 2022. Archived from the original on 6 May 2022. Retrieved 7 May 2022.
"Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates". Moderna, Inc. (Press release). 5 August 2021. Archived from the original on 6 August 2021. Retrieved 5 August 2021.
"Moderna Completes Application to U.S. Food and Drug Administration For Emergency Use Authorization of Omicron-targeting Bivalent COVID-19 Booster Vaccine, mRNA-1273.222". Moderna, Inc. 23 August 2022. Archived from the original on 25 September 2022. Retrieved 25 September 2022.
"Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19". Moderna. 26 July 2020. Archived from the original on 25 April 2021. Retrieved 25 April 2021.
"Moderna COVID-19 Vaccine Update". Moderna, Inc. 25 January 2021. Archived from the original (PDF) on 29 June 2021. Retrieved 26 January 2021.
"Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study". Moderna Inc. (Press release). 24 February 2021. Archived from the original on 24 February 2021. Retrieved 24 February 2021.
"Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern". Moderna, Inc. (Press release). 5 May 2021. Archived from the original on 2 December 2021. Retrieved 22 August 2021.

news.modernatx.com

"EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1". Moderna (Press release). 5 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.
"Taiwan Food & Drug Administration Approves Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1". Moderna (Press release). 2 September 2024. Retrieved 13 September 2024.
"Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2". Moderna (Press release). 22 August 2024. Archived from the original on 26 August 2024. Retrieved 26 August 2024.

modernatx.com

"Storage & Handling". Moderna. 11 August 2021. Archived from the original on 10 January 2022. Retrieved 11 August 2021.

nationalgeographic.com

Kramer J (31 December 2020). "They spent 12 years solving a puzzle. It yielded the first COVID-19 vaccines". National Geographic. Archived from the original on 28 February 2021. Retrieved 8 March 2021.
Kramer J (18 August 2021). "The U.S. plans to authorize boosters—but many already got a third dose". National Geographic. Archived from the original on 10 October 2021. Retrieved 21 August 2021. Getting a booster too soon after primary inoculation might not teach the body's immune system to mount a more robust defense

nature.com

"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (Editorial). 596 (7872): 317. 17 August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262. Archived from the original on 21 October 2021. Retrieved 21 August 2021.

nbcnews.com

"Moderna vaccine trial contractors fail to enroll enough people of color, prompting slowdown". NBC News. Reuters. 6 October 2020. Archived from the original on 19 November 2020. Retrieved 17 November 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

"Elasomeran for prevention of COVID-19". Australian Prescriber. 44 (5): 172. October 2021. doi:10.18773/austprescr.2021.048. PMC 8542485. PMID 34728884. Archived from the original on 14 May 2022. Retrieved 14 May 2022.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. (February 2021). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine". The New England Journal of Medicine. 384 (5): 403–416. doi:10.1056/NEJMoa2035389. PMC 7787219. PMID 33378609.
Mishra SK, Tripathi T (February 2021). "One year update on the COVID-19 pandemic: Where are we now?". Acta Tropica. 214: 105778. doi:10.1016/j.actatropica.2020.105778. PMC 7695590. PMID 33253656.
Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC (February 2021). "COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines". European Review for Medical and Pharmacological Sciences. 25 (3): 1663–1669. doi:10.26355/eurrev_202102_24877. PMID 33629336.
Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 29 March 2021. This article incorporates text from this source, which is in the public domain.
Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al. (June 2021). "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19". N Engl J Med. 384 (23): 2259–2261. doi:10.1056/NEJMc2103916. PMC 8524784. PMID 33822494.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R (September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521. Archived (PDF) from the original on 5 February 2022. Retrieved 15 September 2021.
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. (2 November 2021). "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar". Nature Medicine. 27 (12): 2136–2143. doi:10.1038/s41591-021-01583-4. hdl:10576/24856. ISSN 1546-170X. PMID 34728831. S2CID 241108406. Tables 3 and 5
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). "Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study". BMJ. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165. Tables 6 and 7
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. (June 2021). "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons". The New England Journal of Medicine. 384 (24): 2273–2282. doi:10.1056/NEJMoa2104983. PMC 8117969. PMID 33882218.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (4): 125–129. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. Archived (PDF) from the original on 1 September 2021. Retrieved 25 April 2021.{{cite journal}}: CS1 maint: numeric names: authors list (link) This article incorporates text from this source, which is in the public domain.
Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. (April 2021). "Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2". The New England Journal of Medicine. 384 (13): 1273–1277. doi:10.1056/NEJMc2102131. PMC 7944952. PMID 33657292.
Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. (January 2022). "Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021". JAMA. 327 (4): 331–340. doi:10.1001/jama.2021.24110. PMC 8790664. PMID 35076665.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (November 2020). "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report". The New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912.
Dolgin E (November 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology. doi:10.1038/d41587-020-00022-y. PMID 33239758. S2CID 227176634.
Mateus J, Dan JM, Zhang Z, Moderbacher CR, Lammers M, Goodwin B, et al. (2021). "Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells". Science. 374 (6566): eabj9853. doi:10.1126/science.abj9853. PMC 8542617. PMID 34519540.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–6. doi:10.15585/mmwr.mm695152e1. ISSN 0149-2195. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 21 December 2020. This article incorporates text from this source, which is in the public domain.
"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (Editorial). 596 (7872): 317. 17 August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262. Archived from the original on 21 October 2021. Retrieved 21 August 2021.
"Moderna loses key patent challenge". Nature Biotechnology. 38 (9): 1009. September 2020. doi:10.1038/s41587-020-0674-1. PMID 32887970. S2CID 221504018.

ncbi.nlm.nih.gov

"Elasomeran for prevention of COVID-19". Australian Prescriber. 44 (5): 172. October 2021. doi:10.18773/austprescr.2021.048. PMC 8542485. PMID 34728884. Archived from the original on 14 May 2022. Retrieved 14 May 2022.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. (February 2021). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine". The New England Journal of Medicine. 384 (5): 403–416. doi:10.1056/NEJMoa2035389. PMC 7787219. PMID 33378609.
Mishra SK, Tripathi T (February 2021). "One year update on the COVID-19 pandemic: Where are we now?". Acta Tropica. 214: 105778. doi:10.1016/j.actatropica.2020.105778. PMC 7695590. PMID 33253656.
Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 29 March 2021. This article incorporates text from this source, which is in the public domain.
Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al. (June 2021). "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19". N Engl J Med. 384 (23): 2259–2261. doi:10.1056/NEJMc2103916. PMC 8524784. PMID 33822494.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R (September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521. Archived (PDF) from the original on 5 February 2022. Retrieved 15 September 2021.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). "Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study". BMJ. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165. Tables 6 and 7
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. (June 2021). "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons". The New England Journal of Medicine. 384 (24): 2273–2282. doi:10.1056/NEJMoa2104983. PMC 8117969. PMID 33882218.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (4): 125–129. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. Archived (PDF) from the original on 1 September 2021. Retrieved 25 April 2021.{{cite journal}}: CS1 maint: numeric names: authors list (link) This article incorporates text from this source, which is in the public domain.
Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. (April 2021). "Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2". The New England Journal of Medicine. 384 (13): 1273–1277. doi:10.1056/NEJMc2102131. PMC 7944952. PMID 33657292.
Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. (January 2022). "Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021". JAMA. 327 (4): 331–340. doi:10.1001/jama.2021.24110. PMC 8790664. PMID 35076665.
"GenBank ID MN908947.3". National Center for Biotechnology Information. 18 March 2020. Archived from the original on 11 January 2022. Retrieved 11 July 2021.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (November 2020). "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report". The New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912.
Mateus J, Dan JM, Zhang Z, Moderbacher CR, Lammers M, Goodwin B, et al. (2021). "Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells". Science. 374 (6566): eabj9853. doi:10.1126/science.abj9853. PMC 8542617. PMID 34519540.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–6. doi:10.15585/mmwr.mm695152e1. ISSN 0149-2195. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 21 December 2020. This article incorporates text from this source, which is in the public domain.

nih.gov

"NIH clinical trial of investigational vaccine for COVID-19 begins". National Institutes of Health (NIH). 16 March 2020. Archived from the original on 19 March 2020. Retrieved 18 March 2020.
Bryant E (5 October 2021). "Moderna COVID-19 vaccine generates long-lasting immune memory". NIH Research Matters. National Institutes of Health. Archived from the original on 10 November 2021. Retrieved 10 November 2021.
"Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine". National Institutes of Health (NIH). 15 November 2020. Archived from the original on 4 January 2021. Retrieved 19 December 2020.
"Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine". National Institutes of Health. 18 December 2020. Archived from the original on 19 March 2021. Retrieved 19 December 2020.

dailymed.nlm.nih.gov

"Spikevax- covid-19 vaccine, mrna injection, suspension". DailyMed. 1 January 2022. Archived from the original on 18 June 2022. Retrieved 17 June 2022.
"Moderna COVID-19 Vaccine- cx-024414 injection, suspension". DailyMed. 17 June 2022. Archived from the original on 18 June 2022. Retrieved 17 June 2022.

npr.org

Palca J (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.

nps.org.au

"Elasomeran for prevention of COVID-19". Australian Prescriber. 44 (5): 172. October 2021. doi:10.18773/austprescr.2021.048. PMC 8542485. PMID 34728884. Archived from the original on 14 May 2022. Retrieved 14 May 2022.

nytimes.com

Stevis-Gridneff M (6 January 2021). "The E.U. drug regulator approves the Moderna vaccine". The New York Times. Archived from the original on 6 August 2021. Retrieved 5 August 2021.
Grady D (16 November 2020). "Early Data Show Moderna's Coronavirus Vaccine Is 94.5% Effective". The New York Times. Archived from the original on 24 February 2021. Retrieved 25 April 2021.
Zimmer C (20 November 2020). "2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works". The New York Times. Archived from the original on 22 November 2020. Retrieved 21 November 2020.
McDonnell Nieto del Rio G (15 January 2021). "Covid-19: Over Two Million Around the World Have Died From the Virus". The New York Times. Archived from the original on 18 January 2021. Retrieved 18 January 2021.
Grady D, Mandavilli A, Thomas K (25 January 2021). "Is the Covid-19 Vaccine Effective Against New South African Variant?". The New York Times. Archived from the original on 10 January 2022. Retrieved 25 January 2021.
Stevis-Gridneff M, Sanger-Katz M, Weiland N (18 December 2020). "A European Official Reveals a Secret: The U.S. Is Paying More for Coronavirus Vaccines". The New York Times. Archived from the original on 28 March 2021. Retrieved 19 December 2020.

pfizer.com

"Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA". Pfizer (Press release). 19 February 2021. Archived from the original on 26 April 2021. Retrieved 19 February 2021.

pharmatimes.com

Parsons L (28 October 2020). "UK's MHRA starts rolling review of Moderna's COVID-19 vaccine". PharmaTimes. Archived from the original on 30 November 2020. Retrieved 4 December 2020.

pm.gc.ca

"New agreements to secure additional vaccine candidates for COVID-19". Prime Minister's Office, Government of Canada. 25 September 2020. Archived from the original on 10 January 2022. Retrieved 4 December 2020.

politico.eu

"Moderna to double EU vaccine manufacturing with new Dutch site". Politico. 2 June 2021. Archived from the original on 25 December 2022. Retrieved 25 December 2022.

rapidmicrobiology.com

"Moderna Use Roche Antibody Test During Vaccine Trials". rapidmicrobiology.com. 10 December 2020. Archived from the original on 10 January 2022. Retrieved 13 December 2020.

reuters.com

Steenhuysen J, Kelland K (24 January 2020). "With Wuhan virus genetic code in hand, scientists begin work on a vaccine". Reuters. Archived from the original on 25 January 2020. Retrieved 26 January 2020.
Burger L (1 December 2020). "COVID-19 vaccine sprint as Pfizer-BioNTech, Moderna seek emergency EU approval". Reuters. Archived from the original on 3 December 2020. Retrieved 4 December 2020.
"Singapore becomes first in Asia to approve Moderna's COVID-19 vaccine". Reuters. 3 February 2021. Archived from the original on 10 January 2022. Retrieved 3 February 2021.
"Japan's Takeda to import 50 million doses of Moderna's COVID-19 vaccine, raises profit forecast". Reuters. 29 October 2020. Archived from the original on 9 July 2021. Retrieved 2 July 2021.
Miller J (12 January 2021). "Swiss drugs regulator approves Moderna's COVID-19 vaccine". Reuters. Archived from the original on 12 January 2021. Retrieved 17 January 2021.
"Moderna aims to price coronavirus vaccine at $50–$60 per course: FT". Reuters. 28 July 2020. Archived from the original on 25 July 2021. Retrieved 20 March 2021.
Guarascio F (24 November 2020). "EU secures 160 million doses of Moderna's COVID-19 vaccine". Reuters. Archived from the original on 24 November 2020. Retrieved 25 November 2020.
Taylor M, Respaut R (7 July 2020). "Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials". Reuters. Archived from the original on 16 November 2020. Retrieved 10 July 2020.
"Fact Check-Moderna's COVID-19 vaccine does not contain luciferin or luciferase". Reuters. 6 May 2021. Archived from the original on 3 November 2021. Retrieved 2 November 2021.

semanticscholar.org

api.semanticscholar.org

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. (2 November 2021). "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar". Nature Medicine. 27 (12): 2136–2143. doi:10.1038/s41591-021-01583-4. hdl:10576/24856. ISSN 1546-170X. PMID 34728831. S2CID 241108406. Tables 3 and 5
Dolgin E (November 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology. doi:10.1038/d41587-020-00022-y. PMID 33239758. S2CID 227176634.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–6. doi:10.15585/mmwr.mm695152e1. ISSN 0149-2195. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 21 December 2020. This article incorporates text from this source, which is in the public domain.
"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (Editorial). 596 (7872): 317. 17 August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262. Archived from the original on 21 October 2021. Retrieved 21 August 2021.
"Moderna loses key patent challenge". Nature Biotechnology. 38 (9): 1009. September 2020. doi:10.1038/s41587-020-0674-1. PMID 32887970. S2CID 221504018.

snopes.com

Lee J (14 May 2021). "Do Videos Show Magnets Sticking to People's Arms After COVID-19 Vaccine?". Snopes.com. Archived from the original on 9 November 2021. Retrieved 7 June 2021.
Evon D (2 November 2021). "'Luciferase' Is Not an Ingredient in COVID-19 Vaccines". Snopes.com. Archived from the original on 10 January 2022.

sps.nhs.uk

"Understanding the characteristics of Spikevax (JN.1) vaccine". Specialist Pharmacy Service. 10 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.

statnews.com

Branswell H (2 February 2021). "Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson". Archived from the original on 1 February 2022. Retrieved 28 March 2021.
Herper M, Garde D (14 July 2020). "First data for Moderna Covid-19 vaccine show it spurs an immune response". Stat. Archived from the original on 14 July 2020. Retrieved 15 July 2020.
Krubiner C, Faden RR, Karron RA (9 December 2020). "FDA: Leave the door open to Covid-19 vaccination for pregnant and lactating health workers". STAT. Archived from the original on 10 January 2022.
Branswell H (19 May 2020). "Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccine". Stat. Archived from the original on 16 November 2020. Retrieved 19 May 2020.

straitstimes.com

Khalik S (1 February 2021). "How Singapore picked its Covid-19 vaccines". The Straits Times. Archived from the original on 31 January 2021. Retrieved 1 February 2021.

swissinfo.ch

"Swiss factory rushes to prepare for Moderna Covid-19 vaccine". SWI swissinfo.ch. 7 October 2020. Archived from the original on 16 November 2020. Retrieved 7 October 2020.

swissmedic.ch

"Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland". Swissmedic (Press release). 29 August 2022. Archived from the original on 29 August 2022. Retrieved 1 September 2022.
"Swissmedic grants authorisation for the COVID-19 vaccine from Moderna". Swissmedic (Press release). 12 January 2020. Archived from the original on 11 February 2021. Retrieved 12 January 2020.
"Swissmedic approves indication extension for Spikevax vaccine for 12- to 17-year-olds". Swissmedic (Press release). 11 June 2021. Archived from the original on 18 June 2022. Retrieved 5 July 2022.
"Moderna COVID-19 vaccine authorised in Switzerland for children aged 6 to 11 years". Swissmedic (Press release). 13 May 2022. Archived from the original on 16 June 2022. Retrieved 5 July 2022.
"COVID-19 vaccines from Moderna and Pfizer/BioNTech: Swissmedic approves third vaccination for certain population groups". Swissmedic (Press release). 26 October 2021. Archived from the original on 30 May 2022. Retrieved 5 July 2022.
"Swissmedic approves booster dose of the Moderna COVID-19 vaccine for adults aged 18 and over". Swissmedic (Press release). 26 October 2021. Archived from the original on 30 May 2022. Retrieved 5 July 2022.

takeda.com

"Takeda Announces Approval of Moderna's COVID-19 Vaccine in Japan" (Press release). Takeda. 21 May 2021. Archived from the original on 23 December 2021. Retrieved 29 May 2021.
"Start of a Japanese Clinical Study of TAK-919, Moderna's COVID-19 Vaccine Candidate" (Press release). Takeda. 21 January 2021. Archived from the original on 25 February 2021. Retrieved 11 March 2021.

tga.gov.au

"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
"Spikevax". Therapeutic Goods Administration (TGA). 9 August 2021. Archived from the original on 28 August 2021. Retrieved 28 August 2021.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
"COVID-19 vaccines regulatory status". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 8 October 2023. Retrieved 8 October 2023.
"COVID-19 vaccine: Spikevax (elasomeran)". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 October 2023.
"COVID-19 vaccine: Spikevax (elasomeran)". Therapeutic Goods Administration (TGA). 9 August 2021. Archived from the original on 28 August 2021. Retrieved 28 August 2021.
"TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age group". Therapeutic Goods Administration (TGA). 4 September 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
"AusPAR: Elasomeran". Therapeutic Goods Administration (TGA). 23 February 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
"AusPAR: Elasomeran (mRNA-1273)". Therapeutic Goods Administration (TGA). 9 December 2021. Archived from the original on 24 March 2022. Retrieved 24 March 2022.
"Spikevax Bivalent Original/Omicron". Therapeutic Goods Administration. 1 September 2022. Archived from the original on 1 October 2022. Retrieved 1 October 2022.
"Spikevax bivalent Original/Omicron BA.4-5". Therapeutic Goods Administration (TGA). 23 February 2023. Archived from the original on 24 February 2023. Retrieved 8 April 2023.
"Therapeutic Goods (Poisons Standard) (COVID-19 Vaccine - Moderna) (Elasomeran and Imelasomeran) Labelling Exemption 2022". Therapeutic Goods Administration (TGA). 31 August 2022. Retrieved 17 September 2023.
"TGA provisionally approves Moderna bivalent COVID-19 vaccine for use as a booster dose in adults" (Press release). Therapeutic Goods Administration. 30 August 2022. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
"COVID-19 vaccine: Spikevax Bivalent Original/Omicron (elasomeran/imelasomeran)". Therapeutic Goods Administration. 23 September 2022.
"TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran". Therapeutic Goods Administration (TGA) (Press release). 24 June 2021. Archived from the original on 27 June 2021. Retrieved 29 June 2021.

ebs.tga.gov.au

"Spikevax (elasomeran) Covid-19 Vaccine Product Information Licence" (PDF). Therapeutic Goods Administration (TGA). 18 August 2021. Archived from the original on 28 August 2021. Retrieved 28 August 2021.
"Summary For Artg Entry: 370599 Spikevax (elasomeran) Covid-19 Vaccine 0.2 Mg/Ml Suspension For Injection Vial" (PDF). Therapeutic Goods Administration (TGA). Retrieved 28 August 2021.^{[dead link‍]}

the-scientist.com

Tenn C (6 October 2021). "Moderna Vaccine Paused for Young People in Two European Countries". The Scientist. Archived from the original on 3 October 2022. Retrieved 3 October 2022.

theguardian.com

"Donald Trump appears to admit Covid is 'running wild' in the US". The Guardian. 22 November 2020. Archived from the original on 22 November 2020. Retrieved 22 November 2020. Moderna told the German weekly Welt am Sonntag that it will charge governments between $25 and $37 per dose of its Covid vaccine candidate, depending on the amount ordered.

thehill.com

Williams J (29 April 2021). "Moderna doubling COVID-19 vaccine production". The Hill. Archived from the original on 29 April 2021. Retrieved 29 April 2021.

trackvaccines.org

covid19.trackvaccines.org

"COVID-19 Vaccine Tracker: Moderna: mRNA-1273". McGill University. Archived from the original on 1 February 2022.

usatoday.com

Weise E (7 April 2021). "COVID-19 toes, Moderna arm, all-body rash: Vaccines can cause skin reactions but aren't dangerous, study says". USA Today. Archived from the original on 1 February 2022.
Clouse A (24 November 2020). "Fact check: Moderna vaccine funded by government spending, with notable private donation". USA Today. Archived from the original on 25 April 2021. Retrieved 25 April 2021.
Luthra S (23 November 2020). "Pregnant women haven't been included in promising COVID-19 vaccine trials". USA Today. Archived from the original on 10 January 2022.

verifythis.com

Winter DE, Loe M (14 September 2023). "Florida Surgeon General's claim that updated COVID vaccines weren't clinically tested, including on humans, is misleading". VERIFY. Archived from the original on 15 September 2023. Retrieved 15 September 2023.

virological.org

Jeong DE, McCoy M, Artiles K, Ilbay O, Fire A, Nadeau K, et al. (23 March 2021). "Assemblies of putative SARS-CoV2-spike-encoding mRNA sequences for vaccines BNT-162b2 and mRNA-1273". Virological.org. Archived from the original on 1 February 2022.

vnexpress.net

e.vnexpress.net

Nga L (29 June 2021). "Vietnam approves Moderna Covid vaccine for emergency use". VnExpress. Archived from the original on 1 July 2021. Retrieved 1 July 2021.

washingtonpost.com

Johnson CY (6 December 2020). "A gamble pays off in 'spectacular success': How the leading coronavirus vaccines made it to the finish line". The Washington Post. Archived from the original on 6 March 2021. Retrieved 9 December 2020.

web.archive.org

"Spikevax- covid-19 vaccine, mrna injection, suspension". DailyMed. 1 January 2022. Archived from the original on 18 June 2022. Retrieved 17 June 2022.
"Spikevax (previously COVID-19 Vaccine Moderna) EPAR". European Medicines Agency (EMA). 4 January 2021. Archived from the original on 1 February 2022. Retrieved 31 January 2022.
"Takeda Announces Approval of Moderna's COVID-19 Vaccine in Japan" (Press release). Takeda. 21 May 2021. Archived from the original on 23 December 2021. Retrieved 29 May 2021.
"Elasomeran for prevention of COVID-19". Australian Prescriber. 44 (5): 172. October 2021. doi:10.18773/austprescr.2021.048. PMC 8542485. PMID 34728884. Archived from the original on 14 May 2022. Retrieved 14 May 2022.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
"Spikevax". Therapeutic Goods Administration (TGA). 9 August 2021. Archived from the original on 28 August 2021. Retrieved 28 August 2021.
"Spikevax (elasomeran) Covid-19 Vaccine Product Information Licence" (PDF). Therapeutic Goods Administration (TGA). 18 August 2021. Archived from the original on 28 August 2021. Retrieved 28 August 2021.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
"COVID-19 vaccines regulatory status". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 8 October 2023. Retrieved 8 October 2023.
"COVID-19 vaccine: Spikevax (elasomeran)". Therapeutic Goods Administration (TGA). 9 August 2021. Archived from the original on 28 August 2021. Retrieved 28 August 2021.
"TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age group". Therapeutic Goods Administration (TGA). 4 September 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
"AusPAR: Elasomeran". Therapeutic Goods Administration (TGA). 23 February 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
"AusPAR: Elasomeran (mRNA-1273)". Therapeutic Goods Administration (TGA). 9 December 2021. Archived from the original on 24 March 2022. Retrieved 24 March 2022.
"Spikevax Bivalent Original/Omicron". Therapeutic Goods Administration. 1 September 2022. Archived from the original on 1 October 2022. Retrieved 1 October 2022.
"Spikevax bivalent Original/Omicron BA.4-5". Therapeutic Goods Administration (TGA). 23 February 2023. Archived from the original on 24 February 2023. Retrieved 8 April 2023.
Rosário M (26 June 2023). "Anvisa aprova vacina bivalente da Moderna para Covid-19". O Globo (in Brazilian Portuguese). Archived from the original on 22 May 2024. Retrieved 21 June 2024.
"Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2)". Health Canada. 23 December 2020. Archived from the original on 23 December 2020. Retrieved 23 December 2020.
"Regulatory Decision Summary - COVID-19 Vaccine Moderna". Health Canada. 27 August 2021. Archived from the original on 27 August 2021. Retrieved 28 August 2021.
"Spikevax (elasomeran mRNA vaccine) Monograph" (PDF). Archived from the original (PDF) on 3 December 2021.
"Regulatory Decision Summary - Spikevax". Health Canada. 13 November 2020. Archived from the original on 17 September 2021. Retrieved 18 September 2021.
"Summary Basis of Decision (SBD) for Spikevax". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
"Summary of Product Characteristics for Spikevax". Medicines and Healthcare products Regulatory Agency (MHRA). 20 August 2021. Archived from the original on 18 February 2021. Retrieved 29 August 2021.
"Conditions of Authorisation for COVID-19 Vaccine Moderna". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Archived from the original on 18 February 2021. Retrieved 29 August 2021.
"Regulatory approval of Spikevax (formerly COVID-19 Vaccine Moderna)". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Archived from the original on 28 August 2021. Retrieved 29 August 2021.
"Summary of the Public Assessment Report for Spikevax". Medicines and Healthcare products Regulatory Agency (MHRA). 19 February 2021. Archived from the original on 22 April 2021. Retrieved 29 August 2021.
"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived from the original (PDF) on 14 August 2021. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years Through 17 Years of Age" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived (PDF) from the original on 16 July 2022. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 Years through 11 Years of Age" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived (PDF) from the original on 16 July 2022. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 Months Through 5 Years of Age" (PDF). Centers for Disease Control and Prevention (CDC). 11 July 2022. Archived (PDF) from the original on 16 July 2022. Retrieved 14 July 2022. This article incorporates text from this source, which is in the public domain.
"FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA). 11 September 2023. Archived from the original on 11 September 2023. Retrieved 12 September 2023. This article incorporates text from this source, which is in the public domain.
"FDA Takes Key Action by Approving Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 31 January 2022. Archived from the original on 31 January 2022. Retrieved 31 January 2022. This article incorporates text from this source, which is in the public domain.
"Spikevax and Moderna COVID-19 Vaccine". U.S. Food and Drug Administration (FDA). 17 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age". U.S. Food and Drug Administration (FDA) (Press release). 17 June 2022. Archived from the original on 17 June 2022. Retrieved 17 June 2022.
"Fact Sheet for Healthcare Providers Administering Vaccine" (PDF). U.S. Food and Drug Administration (FDA). 31 January 2022. Archived from the original on 1 February 2022. Retrieved 13 August 2021.
"Moderna COVID-19 Vaccine- cx-024414 injection, suspension". DailyMed. 17 June 2022. Archived from the original on 18 June 2022. Retrieved 17 June 2022.
"Moderna COVID-19 Vaccine Emergency Use Authorization" (PDF). U.S. Food and Drug Administration (FDA). 17 June 2022. Archived from the original on 14 August 2021. Retrieved 17 June 2022. This article incorporates text from this source, which is in the public domain.
"European Commission authorises second safe and effective vaccine against COVID-19". European Commission (Press release). 6 January 2021. Archived from the original on 20 January 2021. Retrieved 6 January 2021.
"EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines". European Medicines Agency (Press release). 16 September 2022. Archived from the original on 16 September 2022. Retrieved 18 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Spikevax Product information". Union Register of medicinal products. Archived from the original on 24 January 2021. Retrieved 3 March 2023.
Mandavilli A (19 June 2022). "CDC recommends COVID-19 vaccines for children under 5". The New York Times. Archived from the original on 21 June 2022. Retrieved 21 June 2022.
"Moderna COVID-19 Vaccine". Dosing & Administration. Infectious Diseases Society of America. 4 January 2021. Archived from the original on 20 December 2020. Retrieved 5 January 2021.
"FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals". U.S. Food and Drug Administration (FDA) (Press release). 12 August 2021. Archived from the original on 7 December 2021. Retrieved 13 August 2021. This article incorporates text from this source, which is in the public domain.
"COVID-19 Vaccines for Moderately to Severely Immunocompromised People". U.S. Centers for Disease Control and Prevention (CDC). 13 August 2021. Archived from the original on 10 December 2021. Retrieved 13 August 2021.
"Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform". Moderna (Press release). 19 April 2022. Archived from the original on 6 May 2022. Retrieved 7 May 2022.
"First bivalent COVID-19 booster vaccine approved by UK medicines regulator" (Press release). Medicines and Healthcare products Regulatory Agency (MHRA). 15 August 2022. Archived from the original on 16 August 2022. Retrieved 16 August 2022.
"Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 15 August 2022. Archived from the original on 16 August 2022. Retrieved 16 August 2022.
"Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland". Swissmedic (Press release). 29 August 2022. Archived from the original on 29 August 2022. Retrieved 1 September 2022.
"TGA provisionally approves Moderna bivalent COVID-19 vaccine for use as a booster dose in adults" (Press release). Therapeutic Goods Administration. 30 August 2022. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
"Regulatory Decision Summary - Spikevax Bivalent". Health Canada. 1 September 2022. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
Boisvert N (1 September 2022). "Health Canada approves updated Moderna vaccine for Omicron variant". CBC News. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose" (Press release). U.S. Food and Drug Administration (FDA). 31 August 2022. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
"CDC Recommends the First Updated COVID-19 Booster" (Press release). U.S. Centers for Disease Control and Prevention (CDC). 1 September 2022. Archived from the original on 2 September 2022. Retrieved 1 September 2022.
"COVID-19 Vaccine Tracker: Moderna: mRNA-1273". McGill University. Archived from the original on 1 February 2022.
"Moderna COVID-19 Vaccine". U.S. Food and Drug Administration (FDA). 7 July 2021. Archived from the original on 23 January 2021. Retrieved 5 August 2021.
Stevis-Gridneff M (6 January 2021). "The E.U. drug regulator approves the Moderna vaccine". The New York Times. Archived from the original on 6 August 2021. Retrieved 5 August 2021.
"Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates". Moderna, Inc. (Press release). 5 August 2021. Archived from the original on 6 August 2021. Retrieved 5 August 2021.
"Moderna Completes Application to U.S. Food and Drug Administration For Emergency Use Authorization of Omicron-targeting Bivalent COVID-19 Booster Vaccine, mRNA-1273.222". Moderna, Inc. 23 August 2022. Archived from the original on 25 September 2022. Retrieved 25 September 2022.
"The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know". World Health Organization (WHO). 18 August 2022. Archived from the original on 2 September 2022. Retrieved 1 September 2022.
"Comirnaty and Spikevax: EMA recommendations on extra doses boosters". European Medicines Agency (EMA) (Press release). 4 October 2021. Archived from the original on 11 December 2021. Retrieved 4 October 2021.
Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 (Report). World Health Organization (WHO). February 2021. hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 2 May 2021.
"Background document on the mRNA-1273 vaccine (Moderna) against COVID-19". World Health Organization (WHO). 3 February 2021. Archived from the original on 26 January 2022. Retrieved 25 January 2022.
"Vaccines and Related Biological Products Advisory Committee Meeting" (PDF). U.S. Food and Drug Administration (FDA). 17 December 2020. Archived from the original on 1 January 2022. Retrieved 23 December 2020.
Branswell H (2 February 2021). "Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson". Archived from the original on 1 February 2022. Retrieved 28 March 2021.
Kunzmann K (31 December 2020). "Moderna Vaccine Shows Significant COVID-19 Prevention Efficacy in Phase 3 Data". Contagion Live. Archived from the original on 1 February 2022.
"VRBPAC mRNA-1273 Sponsor Briefing Document" (PDF). Moderna. 17 December 2020. Archived from the original on 13 May 2021. Retrieved 1 January 2021.
Jenco J (16 March 2021). "Moderna testing COVID-19 vaccine in children under 12". AAP News. Archived from the original on 3 November 2021. Retrieved 10 April 2021.
Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 29 March 2021. This article incorporates text from this source, which is in the public domain.
"Moderna says Covid vaccine durable for at least six months". France 24. Agence France-Presse. 5 August 2021. Archived from the original on 11 August 2021. Retrieved 11 August 2021.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521. Archived (PDF) from the original on 5 February 2022. Retrieved 15 September 2021.
"Vaccination Considerations for People Pregnant or Breastfeeding". U.S. Centers for Disease Control and Prevention (CDC). 18 March 2021. Archived from the original on 5 January 2022. Retrieved 24 April 2021. This article incorporates text from this source, which is in the public domain.
Shimabukuro T (1 March 2021). "COVID-19 Vaccine Safety Update" (PDF). U.S. Centers for Disease Control and Prevention. Archived (PDF) from the original on 7 June 2021. Retrieved 30 March 2021.
Smith K (24 April 2021). "New CDC guidance recommends pregnant people get the COVID-19 vaccine". CBS News. Archived from the original on 24 April 2021. Retrieved 24 April 2021.
Weise E (7 April 2021). "COVID-19 toes, Moderna arm, all-body rash: Vaccines can cause skin reactions but aren't dangerous, study says". USA Today. Archived from the original on 1 February 2022.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (4): 125–129. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. Archived (PDF) from the original on 1 September 2021. Retrieved 25 April 2021.{{cite journal}}: CS1 maint: numeric names: authors list (link) This article incorporates text from this source, which is in the public domain.
"Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines". U.S. Centers for Disease Control and Prevention (CDC). 3 June 2022. Archived from the original on 27 June 2021. Retrieved 27 June 2021. This article incorporates text from this source, which is in the public domain.
National Center for Immunization and Respiratory Diseases (23 June 2021). "Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination". Centers for Disease Control and Prevention. Archived from the original on 3 July 2021. Retrieved 2 July 2021.
"COVID-19 vaccines safety update" (PDF). European Medicines Agency. 3 August 2022. Archived (PDF) from the original on 3 August 2022. Retrieved 3 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Auth DR, Powell MB (14 September 2020). "Patent Issues Highlight Risks of Moderna's COVID-19 Vaccine". New York Law Journal. Archived from the original on 15 October 2020. Retrieved 1 December 2020.
Cross R (29 September 2020). "The tiny tweak behind COVID-19 vaccines". Chemical & Engineering News. 98 (38). Archived from the original on 16 February 2021. Retrieved 30 September 2020.
Johnson CY (6 December 2020). "A gamble pays off in 'spectacular success': How the leading coronavirus vaccines made it to the finish line". The Washington Post. Archived from the original on 6 March 2021. Retrieved 9 December 2020.
Kramer J (31 December 2020). "They spent 12 years solving a puzzle. It yielded the first COVID-19 vaccines". National Geographic. Archived from the original on 28 February 2021. Retrieved 8 March 2021.
"GenBank ID MN908947.3". National Center for Biotechnology Information. 18 March 2020. Archived from the original on 11 January 2022. Retrieved 11 July 2021.
Jeong DE, McCoy M, Artiles K, Ilbay O, Fire A, Nadeau K, et al. (23 March 2021). "Assemblies of putative SARS-CoV2-spike-encoding mRNA sequences for vaccines BNT-162b2 and mRNA-1273". Virological.org. Archived from the original on 1 February 2022.
Springer P (24 May 2021). "Fargo firm makes key ingredient for millions of COVID-19 vaccine doses". Grand Forks Herald. Archived from the original on 22 August 2021. Retrieved 25 May 2021.
Mullin R (25 November 2020). "Pfizer, Moderna ready vaccine manufacturing networks". Chemical & Engineering News. American Chemical Society. Archived from the original on 11 December 2020. Retrieved 21 December 2020.
Cote J (4 May 2021). "Moderna to more than double size of Massachusetts facility, transform production and lab space to industrial tech center". MassLive. Archived from the original on 25 July 2021. Retrieved 28 May 2021.
"Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands". www.lonza.com. 2 June 2021. Archived from the original on 25 December 2022. Retrieved 25 December 2022.
"Moderna to double EU vaccine manufacturing with new Dutch site". Politico. 2 June 2021. Archived from the original on 25 December 2022. Retrieved 25 December 2022.
Hopkins JS (6 April 2021). "Moderna Covid-19 Vaccine Production Pace to Increase at Contract Manufacturer Catalent". The Wall Street Journal. Archived from the original on 13 April 2021. Retrieved 13 April 2021.
Loftus P (21 March 2021). "Covid-19 Vaccine Manufacturing in U.S. Races Ahead". The Wall Street Journal. Archived from the original on 28 April 2021. Retrieved 29 April 2021.
Williams J (29 April 2021). "Moderna doubling COVID-19 vaccine production". The Hill. Archived from the original on 29 April 2021. Retrieved 29 April 2021.
Loftus P (29 April 2021). "Moderna to Boost Covid-19 Vaccine Production to Meet Rising Global Demand". The Wall Street Journal. Archived from the original on 29 April 2021. Retrieved 29 April 2021.
"Pfizer-BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling". Pfizer. Archived from the original on 1 February 2022. Retrieved 17 December 2020.
Lovelace Jr B, Higgins-Dunn N (16 November 2020). "Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar". CNBC. Archived from the original on 16 November 2020. Retrieved 17 November 2020.
McGregor G (5 December 2020). "How China's COVID-19 could fill the gaps left by Pfizer, Moderna, AstraZeneca". Fortune. Archived from the original on 12 December 2020. Retrieved 5 December 2020.
"Pfizer's Vaccine Is Out of the Question as Indonesia Lacks Refrigerators: State Pharma Boss". Jakarta Globe. 22 November 2020. Archived from the original on 7 December 2020. Retrieved 5 December 2020.
"Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 25 February 2021. Archived from the original on 25 February 2021. Retrieved 25 February 2021. This article incorporates text from this source, which is in the public domain.
"Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA". Pfizer (Press release). 19 February 2021. Archived from the original on 26 April 2021. Retrieved 19 February 2021.
Steenhuysen J, Kelland K (24 January 2020). "With Wuhan virus genetic code in hand, scientists begin work on a vaccine". Reuters. Archived from the original on 25 January 2020. Retrieved 26 January 2020.
Carey K (26 February 2020). "Increasing number of biopharma drugs target COVID-19 as virus spreads". BioWorld. Archived from the original on 27 February 2020. Retrieved 1 March 2020.
Everett G (27 February 2020). "These 5 drug developers have jumped this week on hopes they can provide a coronavirus treatment". Markets Insider. Archived from the original on 16 November 2020. Retrieved 1 March 2020.
"Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19". Moderna. 26 July 2020. Archived from the original on 25 April 2021. Retrieved 25 April 2021.
Clouse A (24 November 2020). "Fact check: Moderna vaccine funded by government spending, with notable private donation". USA Today. Archived from the original on 25 April 2021. Retrieved 25 April 2021.
Grady D (16 November 2020). "Early Data Show Moderna's Coronavirus Vaccine Is 94.5% Effective". The New York Times. Archived from the original on 24 February 2021. Retrieved 25 April 2021.
"Dolly Parton 'honoured and proud' to help Covid-19 battle". BBC News. 18 November 2020. Archived from the original on 19 August 2021. Retrieved 14 August 2021.
"NIH clinical trial of investigational vaccine for COVID-19 begins". National Institutes of Health (NIH). 16 March 2020. Archived from the original on 19 March 2020. Retrieved 18 March 2020.
Kuznia R, Polglase K, Mezzofiore G (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.
Keown A (7 May 2020). "Moderna moves into Phase II testing of COVID-19 vaccine candidate". BioSpace. Archived from the original on 16 November 2020. Retrieved 9 May 2020.
Blankenship K (1 May 2020). "Moderna aims for a billion COVID-19 shots a year with Lonza manufacturing tie-up". Fierce Pharma. Archived from the original on 16 November 2020.
"Swiss factory rushes to prepare for Moderna Covid-19 vaccine". SWI swissinfo.ch. 7 October 2020. Archived from the original on 16 November 2020. Retrieved 7 October 2020.
Li Y (14 July 2020). "Dow futures jump more than 200 points after Moderna says its vaccine produces antibodies to coronavirus". CNBC. Archived from the original on 16 November 2020. Retrieved 15 July 2020.
Herper M, Garde D (14 July 2020). "First data for Moderna Covid-19 vaccine show it spurs an immune response". Stat. Archived from the original on 14 July 2020. Retrieved 15 July 2020.
Bryant E (5 October 2021). "Moderna COVID-19 vaccine generates long-lasting immune memory". NIH Research Matters. National Institutes of Health. Archived from the original on 10 November 2021. Retrieved 10 November 2021.
Palca J (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
Pagliarulo N, ed. (17 September 2020). "Moderna, in bid for transparency, discloses detailed plan of coronavirus vaccine trial". BioPharma Dive. Archived from the original on 16 November 2020. Retrieved 18 September 2020.
Mascarenhas L (1 October 2020). "Moderna chief says Covid-19 vaccine could be widely available by late March". CNN. Archived from the original on 16 November 2020. Retrieved 2 October 2020.
Cohen E (22 October 2020). "First large-scale US Covid-19 vaccine trial reaches target of 30,000 participants". CNN. Archived from the original on 16 November 2020. Retrieved 23 October 2020.
"Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine". National Institutes of Health (NIH). 15 November 2020. Archived from the original on 4 January 2021. Retrieved 19 December 2020.
"Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine". National Institutes of Health. 18 December 2020. Archived from the original on 19 March 2021. Retrieved 19 December 2020.
Zimmer C (20 November 2020). "2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works". The New York Times. Archived from the original on 22 November 2020. Retrieved 21 November 2020.
Loftus P (16 March 2021). "Moderna Is Testing Its Covid-19 Vaccine on Young Children". The Wall Street Journal. Archived from the original on 16 March 2021. Retrieved 16 March 2021.
"Moderna testing COVID-19 vaccine in children under 12". American Academy of Pediatrics. 16 March 2021. Archived from the original on 3 November 2021. Retrieved 10 April 2021.
Cohen E (30 November 2020). "Moderna applies for FDA authorization for its Covid-19 vaccine". CNN. Archived from the original on 3 December 2020. Retrieved 4 December 2020.
Burger L (1 December 2020). "COVID-19 vaccine sprint as Pfizer-BioNTech, Moderna seek emergency EU approval". Reuters. Archived from the original on 3 December 2020. Retrieved 4 December 2020.
Kuchler H (30 November 2020). "Canada could be among the first to clear Moderna's COVID-19 vaccine for use". The Financial Post. Archived from the original on 4 December 2020. Retrieved 4 December 2020.
Parsons L (28 October 2020). "UK's MHRA starts rolling review of Moderna's COVID-19 vaccine". PharmaTimes. Archived from the original on 30 November 2020. Retrieved 4 December 2020.
"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 18 December 2020. Archived from the original on 17 March 2021. Retrieved 18 December 2020. This article incorporates text from this source, which is in the public domain.
Lee J (16 December 2020). "Moderna nears its first-ever FDA authorization, for its COVID-19 vaccine". MarketWatch. Archived from the original on 16 April 2021. Retrieved 19 December 2020.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–6. doi:10.15585/mmwr.mm695152e1. ISSN 0149-2195. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 21 December 2020. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccines". U.S. Food and Drug Administration. 20 April 2023. Archived from the original on 7 October 2022. Retrieved 23 April 2023.
"Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines". U.S. Food and Drug Administration (Press release). 18 April 2023. Archived from the original on 23 April 2023. Retrieved 23 April 2023.
"Regulatory Decision Summary – Moderna COVID-19 Vaccine". Health Canada. 23 December 2020. Archived from the original on 15 January 2021. Retrieved 23 December 2020.
"Israel authorises use of Moderna's COVID-19 vaccine". Yahoo! News. 4 January 2021. Archived from the original on 5 January 2021. Retrieved 5 January 2021.
"WHO lists Moderna vaccine for emergency use". World Health Organization (WHO) (Press release). 30 April 2021. Archived from the original on 6 May 2021. Retrieved 29 May 2021.
"WHO lists anti-COVID Moderna vaccine for emergency use". Philippine Daily Inquirer. Agence France-Presse. 1 May 2021. Archived from the original on 1 May 2021. Retrieved 1 May 2021.
Lopez V (5 May 2021). "Philippines grants EUA to Moderna's COVID-19 vaccine". GMA News Online. Archived from the original on 5 May 2021. Retrieved 5 May 2021.
"Japan's Takeda to import 50 million doses of Moderna's COVID-19 vaccine, raises profit forecast". Reuters. 29 October 2020. Archived from the original on 9 July 2021. Retrieved 2 July 2021.
"Start of a Japanese Clinical Study of TAK-919, Moderna's COVID-19 Vaccine Candidate" (Press release). Takeda. 21 January 2021. Archived from the original on 25 February 2021. Retrieved 11 March 2021.
Kaul R (29 June 2021). "Moderna's Covid vaccine approved for use in India". Hindustan Times. Archived from the original on 20 October 2021. Retrieved 29 June 2021.
Nga L (29 June 2021). "Vietnam approves Moderna Covid vaccine for emergency use". VnExpress. Archived from the original on 1 July 2021. Retrieved 1 July 2021.
"NPRA Approves Moderna Covid-19 Vaccine". CodeBlue. 5 August 2021. Archived from the original on 7 August 2021. Retrieved 8 August 2021.
"EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU" (Press release). European Medicines Agency (EMA). 6 January 2021. Archived from the original on 17 March 2021. Retrieved 6 January 2021.
"COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU". European Medicines Agency (EMA) (Press release). 23 July 2021. Archived from the original on 26 November 2021. Retrieved 10 November 2021.
Miller J (12 January 2021). "Swiss drugs regulator approves Moderna's COVID-19 vaccine". Reuters. Archived from the original on 12 January 2021. Retrieved 17 January 2021.
"Swissmedic grants authorisation for the COVID-19 vaccine from Moderna". Swissmedic (Press release). 12 January 2020. Archived from the original on 11 February 2021. Retrieved 12 January 2020.
"Swissmedic approves indication extension for Spikevax vaccine for 12- to 17-year-olds". Swissmedic (Press release). 11 June 2021. Archived from the original on 18 June 2022. Retrieved 5 July 2022.
"Moderna COVID-19 vaccine authorised in Switzerland for children aged 6 to 11 years". Swissmedic (Press release). 13 May 2022. Archived from the original on 16 June 2022. Retrieved 5 July 2022.
"COVID-19 vaccines from Moderna and Pfizer/BioNTech: Swissmedic approves third vaccination for certain population groups". Swissmedic (Press release). 26 October 2021. Archived from the original on 30 May 2022. Retrieved 5 July 2022.
"Swissmedic approves booster dose of the Moderna COVID-19 vaccine for adults aged 18 and over". Swissmedic (Press release). 26 October 2021. Archived from the original on 30 May 2022. Retrieved 5 July 2022.
McDonnell Nieto del Rio G (15 January 2021). "Covid-19: Over Two Million Around the World Have Died From the Virus". The New York Times. Archived from the original on 18 January 2021. Retrieved 18 January 2021.
Loftus P. "Moderna Explores Whether Third Covid-19 Vaccine Dose Adds Extra Protection". The Wall Street Journal. Archived from the original on 15 January 2021. Retrieved 18 January 2021.
"Coronavirus Disease 2019". Centers for Disease Control and Prevention (Press release). 10 January 2022. Archived from the original on 4 February 2022. Retrieved 4 February 2022.
"Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months". U.S. Food and Drug Administration (FDA) (Press release). 7 January 2022. Archived from the original on 4 February 2022. Retrieved 4 February 2022.
"EMA evaluating data on booster dose of COVID-19 vaccine Spikevax". European Medicines Agency (EMA) (Press release). 27 September 2021. Archived from the original on 27 September 2021. Retrieved 27 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"ECDC and EMA highlight considerations for additional booster doses of COVID-19 vaccines". European Medicines Agency (EMA) (Press release). 2 September 2021. Archived from the original on 28 September 2021. Retrieved 27 September 2021.
"FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines". U.S. Food and Drug Administration (FDA) (Press release). 21 October 2021. Archived from the original on 7 December 2021. Retrieved 22 October 2021. This article incorporates text from this source, which is in the public domain.
"CDC Expands Eligibility for COVID-19 Booster Shots". U.S. Centers for Disease Control and Prevention (CDC). 21 October 2021. Archived from the original on 7 December 2021. Retrieved 22 October 2021. This article incorporates text from this source, which is in the public domain.
"FDA Expands Eligibility for COVID-19 Vaccine Boosters". U.S. Food and Drug Administration (FDA) (Press release). 19 November 2021. Archived from the original on 19 November 2021. Retrieved 19 November 2021. This article incorporates text from this source, which is in the public domain.
"FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months". U.S. Food and Drug Administration (FDA) (Press release). 7 January 2022. Archived from the original on 7 January 2022. Retrieved 7 January 2022. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 Vaccine Update". Moderna, Inc. 25 January 2021. Archived from the original (PDF) on 29 June 2021. Retrieved 26 January 2021.
"Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study". Moderna Inc. (Press release). 24 February 2021. Archived from the original on 24 February 2021. Retrieved 24 February 2021.
"A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants". ClinicalTrials.gov. 15 June 2021. Archived from the original on 6 August 2021. Retrieved 5 August 2021.
"Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern". Moderna, Inc. (Press release). 5 May 2021. Archived from the original on 2 December 2021. Retrieved 22 August 2021.
"Spikevax Bivalent". Health Canada. 1 September 2022. Archived from the original on 30 October 2022. Retrieved 30 October 2022.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups". U.S. Food and Drug Administration (Press release). 12 October 2022. Archived from the original on 13 October 2022. Retrieved 13 October 2022. This article incorporates text from this source, which is in the public domain.
"Spikevax". U.S. Food and Drug Administration (FDA). 11 September 2023. Archived from the original on 11 September 2023. Retrieved 12 September 2023.
"Moderna COVID-19 Vaccine". U.S. Food and Drug Administration (FDA). 11 September 2023. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
Priddy F (12 September 2023). "Safety and Immunogenicity of Moderna COVID-19 Vaccine (2023-2024 Formula) - Monovalent XBB.1.5 Variant Vaccine" (PDF). Centers for Disease Control and Prevention. Archived (PDF) from the original on 15 September 2023. Retrieved 15 September 2023.
Winter DE, Loe M (14 September 2023). "Florida Surgeon General's claim that updated COVID vaccines weren't clinically tested, including on humans, is misleading". VERIFY. Archived from the original on 15 September 2023. Retrieved 15 September 2023.
"MHRA approves Moderna's adapted COVID-19 vaccine (Spikevax) that targets Omicron XBB.1.5". Medicines and Healthcare products Regulatory Agency (MHRA). 15 September 2023. Archived from the original on 21 September 2023. Retrieved 7 October 2023.
"MHRA approves Spikevax JN.1 COVID-19 vaccines for adults and children from infancy". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). Archived from the original on 3 September 2024. Retrieved 4 September 2024.
"Spikevax JN.1 0.1 mg/mL dispersion for injection". (emc). 3 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.
"Understanding the characteristics of Spikevax (JN.1) vaccine". Specialist Pharmacy Service. 10 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.
"Archived copy" (PDF). Archived (PDF) from the original on 13 September 2024. Retrieved 13 September 2024.{{cite web}}: CS1 maint: archived copy as title (link)
"EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1". Moderna (Press release). 5 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.
"Covid-19, Swissmedic autorizza il vaccino aggiornato di Moderna". Corriere del Ticino (in Italian). 10 September 2024. Archived from the original on 13 September 2024. Retrieved 13 September 2024.
"FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (Press release). 22 August 2024. Archived from the original on 13 September 2024. Retrieved 26 August 2024. This article incorporates text from this source, which is in the public domain.
"Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2". Moderna (Press release). 22 August 2024. Archived from the original on 26 August 2024. Retrieved 26 August 2024.
"TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran". Therapeutic Goods Administration (TGA) (Press release). 24 June 2021. Archived from the original on 27 June 2021. Retrieved 29 June 2021.
"UNII - TYF7YW7ENF". precisionFDA. Archived from the original on 13 September 2024. Retrieved 6 October 2023.
"UNII - 4F9QRS7ZV2". precisionFDA. Archived from the original on 13 September 2024. Retrieved 6 October 2023.
"INN Proposed List 129". World Health Organization (WHO). 1 January 1900. Archived from the original on 13 September 2024. Retrieved 6 October 2023.
"Securing Singapore's access to COVID-19 vaccines". www.gov.sg. Singapore Government. 14 December 2020. Archived from the original on 29 January 2021. Retrieved 1 February 2021.
Khalik S (1 February 2021). "How Singapore picked its Covid-19 vaccines". The Straits Times. Archived from the original on 31 January 2021. Retrieved 1 February 2021.
"Trump says U.S. inks agreement with Moderna for 100 mln doses of COVID-19 vaccine candidate". Yahoo. Reuters. 11 August 2020. Archived from the original on 16 November 2020. Retrieved 12 August 2020.
"Moderna aims to price coronavirus vaccine at $50–$60 per course: FT". Reuters. 28 July 2020. Archived from the original on 25 July 2021. Retrieved 20 March 2021.
"Donald Trump appears to admit Covid is 'running wild' in the US". The Guardian. 22 November 2020. Archived from the original on 22 November 2020. Retrieved 22 November 2020. Moderna told the German weekly Welt am Sonntag that it will charge governments between $25 and $37 per dose of its Covid vaccine candidate, depending on the amount ordered.
Guarascio F (24 November 2020). "EU secures 160 million doses of Moderna's COVID-19 vaccine". Reuters. Archived from the original on 24 November 2020. Retrieved 25 November 2020.
Stevis-Gridneff M, Sanger-Katz M, Weiland N (18 December 2020). "A European Official Reveals a Secret: The U.S. Is Paying More for Coronavirus Vaccines". The New York Times. Archived from the original on 28 March 2021. Retrieved 19 December 2020.
"Annual Report for the fiscal year ended December 31, 2020; 10-K SEC filing" (PDF). Moderna Inc. 16 February 2021. Archived (PDF) from the original on 8 December 2021. Retrieved 3 May 2022.
"Annual Report for the fiscal year ended December 31, 2021; 10-K SEC filing" (PDF). Moderna Inc. 25 February 2022. Archived (PDF) from the original on 7 March 2022. Retrieved 3 May 2022.
"No, Germany hasn't stopped using COVID-19 vaccines". AP News. 14 September 2022. Archived from the original on 3 October 2022. Retrieved 3 October 2022.
Hart R (10 November 2021). "Germany, France Restrict Moderna's Covid Vaccine For Under-30s Over Rare Heart Risk—Despite Surging Cases". Forbes. Archived from the original on 2 October 2022. Retrieved 3 October 2022.
Tenn C (6 October 2021). "Moderna Vaccine Paused for Young People in Two European Countries". The Scientist. Archived from the original on 3 October 2022. Retrieved 3 October 2022.
Taylor C (8 October 2021). "Nordic countries are restricting the use of Moderna's Covid vaccine. Here's why". CNBC. Archived from the original on 2 October 2022. Retrieved 2 October 2022.
Hiltzik M (19 May 2020). "Column: Moderna's vaccine results boosted its share offering – and it's hardly a coincidence". The Los Angeles Times. Archived from the original on 16 November 2020. Retrieved 19 May 2020.
Branswell H (19 May 2020). "Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccine". Stat. Archived from the original on 16 November 2020. Retrieved 19 May 2020.
Taylor M, Respaut R (7 July 2020). "Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials". Reuters. Archived from the original on 16 November 2020. Retrieved 10 July 2020.
"Moderna vaccine trial contractors fail to enroll enough people of color, prompting slowdown". NBC News. Reuters. 6 October 2020. Archived from the original on 19 November 2020. Retrieved 17 November 2020.
"Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots" (Press release). United States Department of Health and Human Services. 18 August 2021. Archived from the original on 7 December 2021. Retrieved 21 August 2021.
"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (Editorial). 596 (7872): 317. 17 August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262. Archived from the original on 21 October 2021. Retrieved 21 August 2021.
"Interim statement on COVID-19 vaccine booster doses" (Press release). World Health Organization. 10 August 2021. Archived from the original on 27 November 2021. Retrieved 26 August 2021.
Kramer J (18 August 2021). "The U.S. plans to authorize boosters—but many already got a third dose". National Geographic. Archived from the original on 10 October 2021. Retrieved 21 August 2021. Getting a booster too soon after primary inoculation might not teach the body's immune system to mount a more robust defense
Lee J (14 May 2021). "Do Videos Show Magnets Sticking to People's Arms After COVID-19 Vaccine?". Snopes.com. Archived from the original on 9 November 2021. Retrieved 7 June 2021.
Fichera A (14 May 2021). "Magnet Videos Refuel Bogus Claim of Vaccine Microchips". FactCheck.org. Annenberg Public Policy Center. Archived from the original on 17 May 2021. Retrieved 7 June 2021.
"COVID-19 Vaccine Myths and Facts" (PDF). Los Angeles County Department of Public Health. 15 December 2021. Archived (PDF) from the original on 25 August 2021. Retrieved 27 August 2021.
"COVID-19 Vaccine Facts". Centers for Disease Control and Prevention. 18 August 2021. Archived from the original on 11 December 2021. Retrieved 27 August 2021.
"Fact Check-Moderna's COVID-19 vaccine does not contain luciferin or luciferase". Reuters. 6 May 2021. Archived from the original on 3 November 2021. Retrieved 2 November 2021.
Vardi N (29 June 2020). "Moderna's Mysterious Coronavirus Vaccine Delivery System". Forbes. Archived from the original on 6 January 2021. Retrieved 1 December 2020.

who.int

"The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know". World Health Organization (WHO). 18 August 2022. Archived from the original on 2 September 2022. Retrieved 1 September 2022.
"Background document on the mRNA-1273 vaccine (Moderna) against COVID-19". World Health Organization (WHO). 3 February 2021. Archived from the original on 26 January 2022. Retrieved 25 January 2022.
"WHO lists Moderna vaccine for emergency use". World Health Organization (WHO) (Press release). 30 April 2021. Archived from the original on 6 May 2021. Retrieved 29 May 2021.
"INN Proposed List 129". World Health Organization (WHO). 1 January 1900. Archived from the original on 13 September 2024. Retrieved 6 October 2023.
"Interim statement on COVID-19 vaccine booster doses" (Press release). World Health Organization. 10 August 2021. Archived from the original on 27 November 2021. Retrieved 26 August 2021.

apps.who.int

Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 (Report). World Health Organization (WHO). February 2021. hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 2 May 2021.

worldcat.org

search.worldcat.org

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. (2 November 2021). "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar". Nature Medicine. 27 (12): 2136–2143. doi:10.1038/s41591-021-01583-4. hdl:10576/24856. ISSN 1546-170X. PMID 34728831. S2CID 241108406. Tables 3 and 5
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–6. doi:10.15585/mmwr.mm695152e1. ISSN 0149-2195. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 21 December 2020. This article incorporates text from this source, which is in the public domain.

wsj.com

Hopkins JS (6 April 2021). "Moderna Covid-19 Vaccine Production Pace to Increase at Contract Manufacturer Catalent". The Wall Street Journal. Archived from the original on 13 April 2021. Retrieved 13 April 2021.
Loftus P (21 March 2021). "Covid-19 Vaccine Manufacturing in U.S. Races Ahead". The Wall Street Journal. Archived from the original on 28 April 2021. Retrieved 29 April 2021.
Loftus P (29 April 2021). "Moderna to Boost Covid-19 Vaccine Production to Meet Rising Global Demand". The Wall Street Journal. Archived from the original on 29 April 2021. Retrieved 29 April 2021.
Loftus P (16 March 2021). "Moderna Is Testing Its Covid-19 Vaccine on Young Children". The Wall Street Journal. Archived from the original on 16 March 2021. Retrieved 16 March 2021.
Loftus P. "Moderna Explores Whether Third Covid-19 Vaccine Dose Adds Extra Protection". The Wall Street Journal. Archived from the original on 15 January 2021. Retrieved 18 January 2021.

yahoo.com

news.yahoo.com

"Israel authorises use of Moderna's COVID-19 vaccine". Yahoo! News. 4 January 2021. Archived from the original on 5 January 2021. Retrieved 5 January 2021.

finance.yahoo.com

"Trump says U.S. inks agreement with Moderna for 100 mln doses of COVID-19 vaccine candidate". Yahoo. Reuters. 11 August 2020. Archived from the original on 16 November 2020. Retrieved 12 August 2020.